ArticleFrontiers in endocrinology2026
Optimal cutoff values of alanine aminotransferase and its derived markers for pediatric MASLD.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The early detection of metabolic dysfunction-associated steatotic liver disease (MASLD) is essential. This study aims to evaluate the diagnostic utility and optimal cutoffs of alanine aminotransferase (ALT) and its derived markers, including the ALT/aspartate aminotransferase (AST) and ALT/high-density lipoprotein cholesterol (HDL) ratios, for predicting pediatric MASLD. Methods: We analyzed data from 1,158 adolescents in the National Health and Nutritional Examination Survey (NHANES) and 263 adolescents from a real-world clinical cohort. MASLD was assessed using vibration-controlled transient elastography in the NHANES cohort and abdominal ultrasonography in the clinical cohort. Logistic regression and receiver operating characteristic (ROC) curve analyses were conducted to evaluate associations and predictive performance. Results: ALT, ALT/AST, and ALT/HDL were significantly associated with MASLD in both datasets, even after adjusting for age and sex (all p < 0.001). In the NHANES cohort, the areas under the ROC curves (AUCs) for ALT, ALT/AST, and ALT/HDL were 0.73, 0.77, and 0.76, respectively, with optimal cutoff values of >14.50 for ALT, >0.74 for ALT/AST, and >0.29 for ALT/HDL in the total population. In the real-world clinical cohort, the corresponding AUCs were 0.84, 0.84, and 0.86, respectively. ALT/HDL demonstrated the highest AUC in both datasets, reaching 0.92 in females in the clinical cohort. Conclusions: ALT and ALT-derived markers are valuable for predicting pediatric MASLD. Among them, the ALT/HDL ratio demonstrated the best predictive performance, indicating that composite indices integrating markers of hepatic injury and metabolic status may enhance early detection of MASLD in children and adolescents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.